Digest Network Come funziona
Network
/
Società
Tr
Non verificato

Tris Pharma, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

14 comunicati stampa

Guarda tutti i comunicati
16/10/2025
Scienza
Psichiatria
Medicina - Varie
Sanità
Igiene alimentare
Biotecnologia
Farmaceutica
Salute
Analisi di mercato
Industria
Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
28/08/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Finanza
Industria
Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
12/06/2025
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Industria
Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
01/05/2025
Eventi
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
01/04/2025
Eventi
Biotecnologia
Sanità
Medicina - Varie
Salute
Farmaceutica
Tris Pharma to Present New Data at AAPM PainConnect Annual Meeting and Showcase Potential of Cebranopadol, a First-in-Class Investigational Dual-NMR Agonist for the Treatment of Pain
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
06/03/2025
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
28/01/2025
Tris Pharma Reports Positive Clinical Results of Intranasal Human Abuse Potential Study Indicating Low Abusability of Cebranopadol, an Investigational, First-in-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
22/01/2025
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
19/11/2024
Psichiatria
Salute
Sanità
Farmaceutica
Biotecnologia
Industria
Tris Pharma Secures Additional ex-US Approvals to Expand Global Availability of Quillivant XR and QuilliChew ER for the Treatment of Attention Deficit Hyperactivity Disorder
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0
01/10/2024
Industria
Psichiatria
Salute
Igiene alimentare
Sanità
Farmaceutica
Biotecnologia
Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States
Fonte
Tris Pharma, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0